Parallel Bio

Parallel Bio is a biotechnology company that has developed the first platform replicating the human immune system in a dish for drug discovery and development. Their platform uses immune organoids—functioning in-vitro replicas of human lymph nodes—combined with AI and high-throughput automation to design and test immunotherapies that work in humans from the start. This approach transcends traditional animal models, which are poor predictors of human outcomes, enabling faster, cheaper, and more effective drug development with reduced risk and cost. Parallel Bio's technology allows for population-scale testing, modeling diverse human immune responses to create safer and more effective therapies. The company actively collaborates with major pharmaceutical and biotech companies, aiming to transform immunotherapy discovery and accelerate the delivery of treatments for previously untreatable diseases. Founded in 2021 and based in Cambridge, Massachusetts, Parallel Bio leverages cutting-edge bioengineering, machine learning, and robotics to revolutionize drug discovery by providing a clinical trial in a dish.